Back to News
Market Impact: 0.25

HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug

Source: reuters.com

Healthcare & BiotechCompany FundamentalsPatents & Intellectual Property
HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug

HUTCHMED will receive a $110 million upfront payment from GSK’s subsidiary (GlaxoSmithKline Intellectual Property (No. 4) Ltd) for rights to an experimental solid-tumor drug. The deal adds near-term funding and indicates continued pharma validation of the asset.

AllMind Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Trial

Market Sentiment

Overall Sentiment

mildly positive

Sentiment Score

0.25

Ticker Sentiment

GSK0.25
HCM0.55

More News